Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.

Autor: Tarcha FV; Instituto Brasileiro de Controle do Câncer , São Paulo , SP , Brazil ., Baccarin ALC; Instituto Brasileiro de Controle do Câncer , São Paulo , SP , Brazil ., Barros LADR; Instituto Brasileiro de Controle do Câncer , São Paulo , SP , Brazil ., Alencar EBA; Instituto Brasileiro de Controle do Câncer , São Paulo , SP , Brazil ., Del Giglio A; Centro Universitário FMABC , Santo André , SP , Brazil ., Cruz FJSM; Instituto Brasileiro de Controle do Câncer , São Paulo , SP , Brazil .; Centro Universitário FMABC , Santo André , SP , Brazil .
Jazyk: angličtina
Zdroj: Einstein (Sao Paulo, Brazil) [Einstein (Sao Paulo)] 2023 Dec 22; Vol. 21, pp. eAO0486. Date of Electronic Publication: 2023 Dec 22 (Print Publication: 2023).
DOI: 10.31744/einstein_journal/2023AO0486
Abstrakt: Objective: To assess the incidence of febrile neutropenia without primary granulocyte colony-stimulating factor prophylaxis in patients undergoing chemotherapy with adjuvant docetaxel and cyclophosphamide, and to evaluate the toxicity profile of brand-name docetaxel (Taxotere ® ) and the generic formulation.
Methods: This retrospective study was conducted using data obtained from electronic medical records of patients treated at a Brazilian cancer center. Patients with breast cancer who underwent adjuvant treatment between January 2016 and June 2019 were selected. Data were analyzed using chi-square and Fisher correlation of variables, and multivariate analyses were adjusted for propensity score.
Results: A total of 231 patients with a mean age of 55.9 years at the time of treatment were included in the study. The majority (93.9%) had luminal histology, 84.8% were at clinical stage I, and 98.2% had a good performance status. The overall incidence of febrile neutropenia in the study population was 13.4% (31 cases). The use of brand-name docetaxel (Taxotere ® ) was the only factor associated with febrile neutropenia occurrence (OR= 3.55, 95%CI= 1.58-7.94, p=0.002).
Conclusion: In patients with breast cancer who require treatment with adjuvant docetaxel and cyclophosphamide regimen, the toxicity profile differs between brand-name and generic docetaxel. Regardless of the formulation used, the incidence of febrile neutropenia was less than 20%, which may allow for the omission of primary prophylactic granulocyte colony-stimulating factor use in this setting.
Databáze: MEDLINE
Externí odkaz: